Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 25, 2007 Brian Orelli	Time to Invest in Stents? Stent devices have seen slumping sales over the last few years. Is it time now to invest in the companies that produce them?
The Motley Fool February 5, 2008 Brian Orelli	Medtronic Endeavors to Compete The U.S. drug-eluting stent market just got a little more crowded, after Medtronic announces that the FDA had approved its Endeavor stent for marketing in the U.S.
The Motley Fool May 28, 2009 Brian Orelli	Boston Scientific Back in an Atomic Way Can its tiny stent save the day?
The Motley Fool December 13, 2006 Stephen Albainy-Jenei	The Latest Standpoint on Stents A panel of experts reaches mixed conclusions on the safety and effectiveness of drug-coated stents. Investors, take note.
The Motley Fool February 2, 2004 Alyce Lomax	Boston Scientific's Stent Hopes Nice quarter, but all eyes should be on the Taxus stent.
The Motley Fool October 13, 2008 Brian Orelli	Too Little Too Late for Boston Scientific The company gets new stent approved, but it should have happened earlier.
The Motley Fool March 27, 2008 Brian Orelli	Tougher Rules Could Help Stent Makers The FDA has finally issued draft guidance on the minimum requirements that it thinks companies need to fulfill to get drug-eluting stents approved.
The Motley Fool December 17, 2007 Brian Orelli	A Range of Changes for Stent Makers The FDA is about to make it harder for drug-eluting stents to win its approval.
The Motley Fool November 28, 2007 Brian Orelli	Abbott's Future as a Stent Maker The FDA likes Abbott's new drug-eluting stent; it seems likely the advisory committee will recommend that it be approved.
The Motley Fool May 14, 2008 Brian Orelli	Abbott Knocks Down Boston Scientific Abbott Labs proves its drug-eluting device works better than its competitors as it presented more data from its ongoing Spirit III trial.
The Motley Fool October 8, 2007 Billy Fisher	Vital Signs at Medtronic The FDA raises question about Medtronic's Endeavor stent. Investors, remember that the company also has a well-diversified product portfolio to protect itself against any unforeseen pitfalls ahead.
The Motley Fool October 23, 2008 Brian Orelli	Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter.
The Motley Fool July 26, 2004 W.D. Crotty	Boston Scientific on the Rebound The medical device maker posts robust earnings, softening the blow of the stent delivery system recall.
The Motley Fool August 6, 2004 Jeff Hwang	Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share?
The Motley Fool August 14, 2008 Brian Orelli	Wald Equation Won't Derail Boston Scientific The Wall Street Journal reanalyzes Boston Scientific's data on its new drug-eluding stent, but will the FDA care?
The Motley Fool January 12, 2007 Billy Fisher	Big Week at Boston Scientific The company's off to a great start so far for 2007. Investors, take note.
The Motley Fool May 27, 2010 Brian Orelli	Ever-Evolving Stent Technology (and How to Profit From It) Stay ahead of the curve.
The Motley Fool July 19, 2005 Stephen D. Simpson	Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note.
BusinessWeek October 29, 2007 Arlene Weintraub	Medtronic's Uncertain Endeavor The drug-coated stent might have made up for Medtronic's recent product recall, but renewed scrutiny of the device has executives scaling back expectations
The Motley Fool February 24, 2004 Alyce Lomax	J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain?
The Motley Fool July 23, 2008 Brian Orelli	Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down.
The Motley Fool June 15, 2011 Brian Orelli	Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market.
The Motley Fool March 8, 2005 Stephen D. Simpson	The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents.
The Motley Fool April 23, 2008 Brian Orelli	Boston Scientific Gets It Done After a rough 2007, it looks like Boston Scientific is turning itself around from the bottom up.
The Motley Fool August 29, 2008 Brian Orelli	Stent Makers Getting Desperate Johnson & Johnson, the first company to bring a drug-eluting stent to the U.S. market, seems like it might be getting a little desperate, as competition increases.
The Motley Fool May 20, 2009 Brian Orelli	Johnson & Johnson Tries to Pull a Travolta Johnson & Johnson seems to be making a comeback, after its drug-eluting stent market share fell precipitously to just 15% in the first quarter.
The Motley Fool September 17, 2007 Brian Orelli	Can't See the Trees for the Forest Meta-analysis finds J&J's drug-coated stents are safer than Boston Scientific's stents, maybe. Can J&J use the complex study results to help their falling stent sales?
The Motley Fool July 7, 2008 Brian Orelli	And Then There Were 4 The number of drug-eluting stent players in the U.S. doubles with the addition of Medtronic's Endeavor and Abbott Labs' Xience V.
The Motley Fool April 19, 2005 Stephen D. Simpson	Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good.
The Motley Fool July 23, 2007 Ryan Fuhrmann	Boston Scientific Still Drowsy Facing continued top-line weakness, the medical device company may have to cut costs. Investors, take note.
The Motley Fool January 29, 2009 Brian Orelli	No Buyer's Remorse at Boston Scientific The pacemakers and defibrillators that Guidant contributed to Boston Scientific's bottom line are still growing strong, but the company had to take a whopping $2.7 billion goodwill writedown because the value of what it purchased has changed.
The Motley Fool May 28, 2004 W.D. Crotty	Boston Scientific's Stent Gold Mine The company is starting two or more years of high profitability.
The Motley Fool February 1, 2005 Stephen D. Simpson	Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth.
The Motley Fool April 8, 2005 Stephen D. Simpson	Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse?
The Motley Fool May 29, 2008 Brian Orelli	Medtronic Sticks It to Boston Scientific Medtronic wins the medical-device patent duel with Boston Scientific.
BusinessWeek August 8, 2005 Amy Barrett	BW 50: In A Bind Over Stents Safety concerns about drug-coated stents from Johnson & Johnson and Boston Scientific could open the way for rivals.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Boston Scientific Regains Consciousness Recent Boston Scientific results show glimmers of hope. At current prices, the risk/reward tradeoff appears favorable enough to warrant a full checkup on the stock.
The Motley Fool September 30, 2009 Brian Orelli	Boston Scientific Pays Up And Johnson & Johnson reaps the rewards.
The Motley Fool September 11, 2007 Billy Fisher	FDA Takes Issue With Boston Scientific Boston Scientific has until later this month to respond to an FDA letter prompted by the company's failure to disclose two of five deaths in a stent trial that the medical device maker abandoned in 2006. Investors take note.
The Motley Fool July 6, 2007 Billy Fisher	Medtronic: For the Broken-Hearted Promising clinical trial could bring a new Medtronic stent to market. Investors, take note.
BusinessWeek September 22, 2003 Faith Arner	When Will This Stent See Circulation? Boston Scientific must clear the FDA, among other hurdles.
The Motley Fool March 17, 2009 Brian Orelli	Stent Wars, Episode III: The Rise of Xience V Johnson & Johnson lose the lead in the stent war race, but this is a marathon, not a footrace.
The Motley Fool August 26, 2008 Brian Orelli	Rapid Exchange of Fire Competitors try to block Abbott's patent extension.
The Motley Fool October 15, 2008 Brian Orelli	Abbott's Stents Aren't (That) Important Abbott's shareholders shouldn't be too focused on drug-eluting stents.
The Motley Fool February 5, 2008 Brian Orelli	Boston Scientific Gets Charged Walloped by charges, Boston Scientific posts a loss for the quarter.
The Motley Fool May 27, 2004 Jeff Hwang	Guidant's Stent Stumble Yesterday, Guidant said that a regulatory filing for marketing approval of its Champion stainless steel stent could be delayed up to six months due to "issues" that may result in "manufacturing process modifications and/or stent design changes."
The Motley Fool November 17, 2006 Brian Lawler	Johnson & Johnson's Good Deal If Conor's stent design can alleviate some of the perceived safety worries about stents, then sales from the Cordis division should spring back up, again making it drive revenue growth for Johnson & Johnson, as it did before this year. Investors, take note.
The Motley Fool October 14, 2005 Stephen D. Simpson	Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is.
BusinessWeek April 17, 2006 Amy Barrett	Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created.
The Motley Fool August 12, 2010 Brian Orelli	Turnaround Signal, or Just Noise on the Decline? Boston Scientific clears up an FDA warning letter -- four years later.